Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Means nothing, just like their pipeline, until approval. Egalet’s products aren’t selling well, but at least they have ADF sales.
BTW, COGS is completely irrelevant of sales are awful.
Market cap comparison:
ELTP: 74M
EGLT: 33M
Interesting, expecially since EGLT has an ADF on the market. EGLT's ADF isn't selling well, similar to other ADFs, but they at least have approval of their tech. EGLT got hit hard after Q1 results, even though sales were much higher (still abysmal) than expected. ADFs are simply not catching on unless the FDA forces it. Don't see that anytime soon.
You are exactly right. This is a wet noodle. Never ending dilutive trickle has this stock capped. Volume is better than yesterday’s non-existent session. Lol
Until the FDA approves a product it will still maintain the CRL status.
Volume proves it. No interest until any sign of confidence is given. That confidence needed will be an approval. This is a show-me stock. Talk is cheap, even more so on the OTC.
I think the undisclosed filing will get approved before then and provide a tiny bump. Also, the Q2 filing may help a little as well, but once again we have zero insight as to what it is, but think it will add a little more confidence in the company since we have 2 companies now reviewing the filings instead of just Elite. I think it minimizes the chances of another CRL.
Of course it is for sale. No one is buying.
FDA said Jul - Oct response on Perc. Can’t imagine FDA would go earlier than their guidance.
As an investor I would greatly favor partnership on first few products. This builds up cash, company name, networks, etc. This buys time so the company can put together a cohesive flying solo strategy on future products. Small companies who try to fly solo on first drug almost always fail miserably. It is way too hard and way too costly to initially do, but there are a few rare exceptions.
Glad to see trading value is nearing $1,500 in this trading session so far. Huuuge!
That is one of my concerns as to whether they’ll slip another update like that in the K. That was a pitiful decision by management, especially when there is no live Q&A.
This is their fiscal year end so 3 months before K is released. Last year late May is when they had an additional PR before their conference call. This is always the toughest period to wait for news, especially when IR does so little as is.
Not afraid at all. I am an investor here, but use realism and analytics as my guide.
Today is far different from when Oxy was approved. No comparison.
FDA will not allow a monopoly, especially for a tiny company like Elite for many reasons. All depends on what the competition looks like and what the FDA approves as ADF. Timing plays a critical role as well. FDA is taking their own sweet time on ADF approvals because their focus on opiates is elsewhere - removal of excess opiates (beyond basic needs) from supply.
I believe Elite’s penetration hinges on a few major factors:
1) Approval of ADF tech for either ER or IR (and timing)
2) Real partnership instead of no name company or going solo
3) Whether FDA will move forward with making non-ADF opiates obsolete. If they do not, penetration will be minimal and 10% is highly unlikely. If FDA does move forward then 10% may be a baseline for some opiate products.
The decline over this time period is minimal. However, the data is only through 2014. It does not include the recent opiate trends which would show a stark declining difference.
No it won’t. Needs an incredible amount of sales to get that high. Not going to happen in this environment.
There is no selling or buying. There is simply no interest.
Holy cow! Did you see that volume?! I think I saw a 100 share trade go through. This stock is ready to spring like a wet noodle.
I think I recall an analogy of a treadmill. Perhaps it needs to be plugged in?
When was the last time he bought? Where are all the other insider purchases?
With the stock price this low the senior team should have been eating up stock left and right with their own cash if they believed in the company. They aren’t and clearly don’t. Get facts straight.
I wasn’t referring to trading shares. Nice try manipulating the intent.
No insiders are buying with their own money. That is a big red flag.
Not unless you are an insider. The incessant dollarland scheme does make sense now.
Opiates are getting a bad wrap. Retailers and pharmacies are clearly getting pressured. Bad news for Elite all around.
When you only have free shares it means you have no skin in the game.
Don’t you think if this stock had even the most remote potential to get to a dollar, 0.50 or even 0.25 that insiders would be buying like crazy? It makes zero sense whatsoever. No insider purchases signify they don’t want their funds locked up because there is nothing happening near term. They choose to invest elsewhere. That is what is disturbing.
Also means lack of buying. Lol
All of it is fictitious at this point so who cares?
Offshore brokers allow it.
Short sellers don’t win in bankruptcy. The stock stops trading.
No. They also just take more opiates
I think the real latest weapon is prescribing significantly fewer opiates to begin with having greater control & minimizing excess opiates that enter the wrong hands. Kudos to Gottlieb for executing this and saving lives & families.
You are exactly right. Hmmmm....was he referring to Perc as well there or which was he referencing?
How many days is the tape painted in the last minute of the session?
Per last cc, Nasrat was thinking Perc & Norco would be approved within the next few months. That is May timeframe. Undisclosed is expected during Q2 or Q3 - I never know if they are talking calendar or fiscal. I think calendar unless specified otherwise.
This stock is a gamble. Lol
I don’t think any will resign. Could be wrong. Boards do very little today. More of an I’ll scratch your back if you scratch mine scenario.
It is a hedge in case stock goes to zero, he still gets paid.
In the end the CEO is the architect. If the house shows zero added value under their leadership, yes the CEO should get just as much, close to nothing. We have a stock here that has gone through an enormous amount of dilution over 5 years with no fruits. Real leadership can execute, rest is just fluff.
He is getting paid in Mikah side deals & interest.
Let’s see his track record shows CRLs only, no approvals with non-arms length transactions to line his pockets. This stuff is better than fiction.
That is about as accurate as hedge funds trading this stock. We haven’t heard anything from Nasrat on what the FDA says. Could be because the requirements are not going to be completed this year.